We conducted a global anti-corruption compliance risk assessment for a publicly-traded international medical device company. The results of this assessment, including the suggested compliance program improvements, were key factors in the DOJ’s decision to not criminally prosecute the company nor require any type of corporate monitoring. This compliance program risk assessment including extensive interviews of international personnel in various corporate functions, review of documents, forensic accounting analysis, and reporting our results to the DOJ.
FCPA Compliance Risk Assessment for Medical Device Company
You Also May Be Interested In:
We represented BioScrip, Inc. in its merger with Option Care Enterprises, Inc. The newly combined company, Option Care Health, Inc., emerges as the largest independent home and alternate site infusion services provider in the United States. Option Care Health’s common stock will be listed on the Nasdaq Global Select Market under the ticker symbol BIOS.
Represented Quest Diagnostics in its acquisition of Mobile Medical Examination Service
Represented Quest Diagnostics in its acquisition of Cleveland HeartLab